Roche Holding AG (ROG.VX)

ROG.VX on Virt-X Level 1

270.40CHF
19 Dec 2014
Price Change (% chg)

CHF-18.30 (-6.34%)
Prev Close
CHF288.70
Open
CHF280.00
Day's High
CHF280.00
Day's Low
CHF270.40
Volume
7,906,242
Avg. Vol
1,516,661
52-wk High
CHF295.80
52-wk Low
CHF233.60

ROG.VX

Chart for ROG.VX

About

Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. It belongs to the Roche Group that operates through subsidiaries and associated companies. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment... (more)

Overall

Beta: 0.90
Market Cap (Mil.): CHF233,373.00
Shares Outstanding (Mil.): 862.56
Dividend: 7.80
Yield (%): 2.88

Financials

  ROG.VX Industry Sector
P/E (TTM): 21.68 37.83 38.47
EPS (TTM): 12.47 -- --
ROI: 26.39 18.99 18.25
ROE: 68.57 19.75 19.13
Search Stocks

Deals of the day- Mergers and acquisitions

(Adds Citigroup, Family Investments, Family Dollar, IMS Health, Roche, Saint-Gobain, Sartorius)

19 Dec 2014

Roche and Italian banks stymie European share rebound

* FTSEurofirst 300 up 0.4 percent after Thursday's 3 pct rally

19 Dec 2014

Roche says agrees to buy Bina Technologies for undisclosed price

ZURICH - Swiss drugmaker Roche said on Friday it had agreed to buy privately-held Bina Technologies for an undisclosed price, the company's second acquisition in two days.

19 Dec 2014

Double blow for Roche as breast cancer, Alzheimer's studies fail

ZURICH/LONDON - Roche suffered a double blow on Friday as two clinical studies of drugs for breast cancer and Alzheimer's disease failed, sparking the biggest percentage fall in its stock in five years.

19 Dec 2014

UPDATE 3-Double blow for Roche as breast cancer, Alzheimer's studies fail

* Breast cancer study fails to prove added Kadcyla benefit

19 Dec 2014

European shares hit by drop in Italian banks, taking shine off rally

* FTSEurofirst 300 down 0.1 pct after Thursday's 3 pct rally

19 Dec 2014

BRIEF-Roche shares down 3 percent after disappointing study results

* Shares open down 3 percent after disappointing study results Source text for Eikon: Further company coverage: (Reporting By Silke Koltrowitz)

19 Dec 2014

Roche drops Alzheimer's drug trial; mixed results in breast cancer study

ZURICH, Dec 19 - Swiss pharma group Roche said it would discontinue a late-stage study of investigational anti-amyloid medicine in pre-dementia Alzheimer's disease, following a pre-planned futility analysis and recommendation by the independent Data Monitoring Committee.

19 Dec 2014

Deals of the day- Mergers and acquisitions

(Adds BNP Paribas, One Equity, Deere, Aer Lingus, Grupo Bimbo, Roche; updates Alcatel Lucent)

18 Dec 2014

UPDATE 1-Roche to pay up to $489 mln for next-generation antibody developer

* Paying $133.75 mln upfront, up to $355 mln in milestone payments

18 Dec 2014

Earnings vs. Estimates

Search Stocks